Organon & Co.
NYSE
Organon & Co.'s latest marketcap:
As of 06/08/2025, Organon & Co.'s market capitalization has reached $2.49 B. According to our data, Organon & Co. is the 5278th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 2.49 B |
| Revenue (ttm) | 6.29 B |
| Net Income (ttm) | 750 M |
| Shares Out | 259.96 M |
| EPS (ttm) | 2.88 |
| Forward PE | 2.51 |
| Ex-Dividend Date | 05/12/2025 |
| Earnings Date | 08/05/2025 |
Organon & Co.'s yearly market capitalization.
| Date | Market Cap | Change (%) |
|---|---|---|
| 06/08/2025 | $2.49 B | -35.32% |
| 12/31/2024 | $3.84 B | 4.25% |
| 12/29/2023 | $3.69 B | -48.12% |
| 12/30/2022 | $7.1 B | -7.98% |
| 12/31/2021 | $7.72 B |
Company Profile
About Organon & Co.
Organon & Co. is a global healthcare company that develops and delivers innovative health solutions through prescription therapies and medical devices. Operating in the United States, Europe, Canada, Japan, Asia Pacific, Latin America, the Middle East, Russia, and Africa, Organon focuses on improving patient outcomes worldwide.
Key Product Portfolios
- Women’s Health: Includes contraception and fertility brands such as Nexplanon, NuvaRing, Cerazette, Follistim AQ, Elonva, and Jada.
- Biosimilars: Features immunology products like Brenzys, Renflexis, and Hadlima, as well as oncology treatments Ontruzant and Aybintio.
- Cardiovascular & Respiratory: Offers cholesterol-modifying medicines (Zetia, Vytorin), hypertension treatments (Cozaar, Hyzaar), and asthma/allergy solutions (Singulair, Nasonex).
- Dermatology & Pain Management: Includes Vtama, Diprosone, Fosamax, and non-opioid pain relief products like Arcoxia and Diprospan.
Customer Base
Organon distributes its products to a diverse network, including:
- Drug wholesalers and retailers
- Hospitals and clinics
- Government agencies
- Health maintenance organizations (HMOs)
- Pharmacy benefit managers (PBMs)
Founded: 1923 | Headquarters: Jersey City, New Jersey
Frequently Asked Questions
-
What is Organon & Co.'s (OGN) current market cap?As of 06/08/2025, Organon & Co. (including the parent company, if applicable) has an estimated market capitalization of $2.49 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Organon & Co. (OGN) rank globally by market cap?Organon & Co. global market capitalization ranking is approximately 5278 as of 06/08/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.